Literature DB >> 32804882

DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.

Sheila E Segura1, Silvana Pedra Nobre1, Yaser R Hussein2, Nadeem R Abu-Rustum3, Britta Weigelt1, Robert A Soslow1, Deborah F DeLair1.   

Abstract

Uterine carcinosarcomas (UCSs) are aggressive neoplasms composed of high-grade malignant epithelial and mesenchymal elements with most (∼90%) showing TP53 abnormalities. A subset, however, shows mismatch repair deficiency (MMR-D). We sought to describe their clinical, morphologic, and molecular features. Clinicopathologic data of MMR-D UCSs were recorded including age, stage, follow-up, mismatch repair and p53 immunohistochemistry (IHC), MLH1 promoter methylation status, and germline alterations, TP53 mutation status, microsatellite instability and mutational burden by massively parallel sequencing. Seventeen (6.2%) MMR-D were identified among 276 UCSs. Of MMR-D UCSs, the median age was 60 years. mismatch repair IHC loss is as follows: MLH1/PMS2 65%, MSH2/MSH6 18%, MSH6 12%, and PMS2 6%. MLH1 promoter methylation and Lynch syndrome was identified in 47% and 12% of cases, respectively. Cases with p53 IHC showed the following patterns: wild-type 70%, aberrant 20%, and equivocal 10%. Of cases with sequencing, 88% were hypermutated and microsatellite instability high. High-grade endometrioid, undifferentiated, and clear cell carcinoma was present in 53%, 41%, and 6% of cases, respectively and 47% also showed a low-grade endometrioid component. Most patients presented at an early stage (67%) and upon follow-up, 18% died of disease, 65% showed no evidence of disease, while 18% are alive with disease. Patients with MMR-D UCS are younger than the reported median age (70 y) for traditional UCS and most do not show p53 abnormalities. Low-grade endometrioid and undifferentiated carcinoma were seen in approximately half of all cases. Although UCSs have a high tendency for early extrauterine spread, most patients in our cohort presented at an early stage and at follow-up were no evidence of disease. MMR-D UCSs display distinct clinical, morphologic, and molecular features compared with traditional UCSs.

Entities:  

Mesh:

Year:  2020        PMID: 32804882      PMCID: PMC8259346          DOI: 10.1097/PAS.0000000000001561

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  36 in total

1.  Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.

Authors:  K Matsuo; Y Takazawa; M S Ross; E Elishaev; I Podzielinski; M Yunokawa; T B Sheridan; S H Bush; M M Klobocista; E A Blake; T Takano; S Matsuzaki; T Baba; S Satoh; M Shida; T Nishikawa; Y Ikeda; S Adachi; T Yokoyama; M Takekuma; K Fujiwara; Y Hazama; D Kadogami; M N Moffitt; S Takeuchi; M Nishimura; K Iwasaki; N Ushioda; M S Johnson; M Yoshida; A Hakam; S W Li; A M Richmond; H Machida; P Mhawech-Fauceglia; Y Ueda; K Yoshino; K Yamaguchi; T Oishi; H Kajiwara; K Hasegawa; M Yasuda; K Kawana; K Suda; T M Miyake; T Moriya; Y Yuba; T Morgan; T Fukagawa; A Wakatsuki; T Sugiyama; T Pejovic; T Nagano; K Shimoya; M Andoh; Y Shiki; T Enomoto; T Sasaki; K Fujiwara; M Mikami; M Shimada; I Konishi; T Kimura; M D Post; M M Shahzad; D D Im; H Yoshida; K Omatsu; F R Ueland; J L Kelley; R G Karabakhtsian; L D Roman
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

2.  Integrated Molecular Characterization of Uterine Carcinosarcoma.

Authors:  Andrew D Cherniack; Hui Shen; Vonn Walter; Chip Stewart; Bradley A Murray; Reanne Bowlby; Xin Hu; Shiyun Ling; Robert A Soslow; Russell R Broaddus; Rosemary E Zuna; Gordon Robertson; Peter W Laird; Raju Kucherlapati; Gordon B Mills; John N Weinstein; Jiashan Zhang; Rehan Akbani; Douglas A Levine
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

3.  Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Authors:  Tjalling Bosse; Remi A Nout; Jessica N McAlpine; Melissa K McConechy; Heidi Britton; Yaser R Hussein; Carlene Gonzalez; Raji Ganesan; Jane C Steele; Beth T Harrison; Esther Oliva; August Vidal; Xavier Matias-Guiu; Nadeem R Abu-Rustum; Douglas A Levine; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

4.  Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.

Authors:  Y Iwasa; H Haga; I Konishi; Y Kobashi; K Higuchi; E Katsuyama; S Minamiguchi; H Yamabe
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

5.  Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.

Authors:  Nisha Bansal; Thomas J Herzog; Venkatraman E Seshan; Peter B Schiff; William M Burke; Carmel J Cohen; Jason D Wright
Journal:  Obstet Gynecol       Date:  2008-07       Impact factor: 7.661

6.  Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Authors:  Zsofia K Stadler; Francesca Battaglin; Sumit Middha; Jaclyn F Hechtman; Christina Tran; Andrea Cercek; Rona Yaeger; Neil H Segal; Anna M Varghese; Diane L Reidy-Lagunes; Nancy E Kemeny; Erin E Salo-Mullen; Asad Ashraf; Martin R Weiser; Julio Garcia-Aguilar; Mark E Robson; Kenneth Offit; Maria E Arcila; Michael F Berger; Jinru Shia; David B Solit; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

7.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

Authors:  Aline Talhouk; Lien N Hoang; Melissa K McConechy; Quentin Nakonechny; Joyce Leo; Angela Cheng; Samuel Leung; Winnie Yang; Amy Lum; Martin Köbel; Cheng-Han Lee; Robert A Soslow; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Gynecol Oncol       Date:  2016-07-14       Impact factor: 5.482

8.  Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

Authors:  Ahmet Zehir; Jaclyn F Hechtman; Sumit Middha; Liying Zhang; Khedoudja Nafa; Gowtham Jayakumaran; Donna Wong; Hyunjae R Kim; Justyna Sadowska; Michael F Berger; Deborah F Delair; Jinru Shia; Zsofia Stadler; David S Klimstra; Marc Ladanyi
Journal:  JCO Precis Oncol       Date:  2017-10-03

Review 9.  High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Authors:  Rajmohan Murali; Ben Davidson; Oluwole Fadare; Joseph A Carlson; Christopher P Crum; C Blake Gilks; Julie A Irving; Anais Malpica; Xavier Matias-Guiu; W Glenn McCluggage; Khush Mittal; Esther Oliva; Vinita Parkash; Joanne K L Rutgers; Paul N Staats; Colin J R Stewart; Carmen Tornos; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

10.  Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Authors:  Ellen Stelloo; Tjalling Bosse; Remi A Nout; Helen J MacKay; David N Church; Hans W Nijman; Alexandra Leary; Richard J Edmondson; Melanie E Powell; Emma J Crosbie; Henry C Kitchener; Linda Mileshkin; Pamela M Pollock; Vincent T Smit; Carien L Creutzberg
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

View more
  7 in total

Review 1.  Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature.

Authors:  Giacomo Santandrea; Simonetta Piana; Riccardo Valli; Magda Zanelli; Elisa Gasparini; Antonio De Leo; Vincenzo Dario Mandato; Andrea Palicelli
Journal:  Diagnostics (Basel)       Date:  2021-01-29

2.  L1CAM Expression in Microcystic, Elongated, and Fragmented (MELF) Glands Predicts Lymph Node Involvement in Endometrial Carcinoma.

Authors:  Damiano Arciuolo; Antonio Travaglino; Angela Santoro; Giulia Scaglione; Nicoletta D'Alessandris; Michele Valente; Frediano Inzani; Rossella Accarino; Alessia Piermattei; Roberta Benvenuto; Antonio Raffone; Camilla Nero; Silvia Pelligra; Francesco Fanfani; Massimo Mascolo; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

Review 3.  The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning.

Authors:  Sarah Fremond; Viktor Hendrik Koelzer; Nanda Horeweg; Tjalling Bosse
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 4.  Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.

Authors:  Antonio Raffone; Antonio Travaglino; Diego Raimondo; Manuela Maletta; Valentino De Vivo; Umberto Visiello; Paolo Casadio; Renato Seracchioli; Fulvio Zullo; Luigi Insabato; Antonio Mollo
Journal:  Int J Gynaecol Obstet       Date:  2021-12-11       Impact factor: 4.447

5.  Inflammatory leiomyosarcoma/rhabdomyoblastic tumor: A report of two cases with novel genetic findings.

Authors:  Madina Sukhanova; Farres Obeidin; Lukas Streich; Borislav A Alexiev
Journal:  Genes Chromosomes Cancer       Date:  2022-06-30       Impact factor: 4.263

Review 6.  TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.

Authors:  Damiano Arciuolo; Antonio Travaglino; Antonio Raffone; Diego Raimondo; Angela Santoro; Daniela Russo; Silvia Varricchio; Paolo Casadio; Frediano Inzani; Renato Seracchioli; Antonio Mollo; Massimo Mascolo; Gian Franco Zannoni
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

Review 7.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

Authors:  Angela Santoro; Giuseppe Angelico; Antonio Travaglino; Frediano Inzani; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Vincenzo Fiorentino; Antonio Raffone; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.